# Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

> **NCT07311993** · PHASE1 · RECRUITING · sponsor: **Cellectar Biosciences, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Iopofosine I 131
- **DRUG:** CLR 125

## Key facts

- **NCT ID:** NCT07311993
- **Lead sponsor:** Cellectar Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2028-02
- **Final completion:** 2029-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311993, "Phase 1 Study of CLR 125 in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07311993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*